First Time Loading...

Anebulo Pharmaceuticals Inc
NASDAQ:ANEB

Watchlist Manager
Anebulo Pharmaceuticals Inc Logo
Anebulo Pharmaceuticals Inc
NASDAQ:ANEB
Watchlist
Price: 2.87 USD 3.24%
Updated: Mar 29, 2024

Intrinsic Value

Anebulo Pharmaceuticals, Inc. engages in the provision of pharmaceutical services. [ Read More ]

There is not enough data to reliably calculate the intrinsic value of ANEB.

Key Points:
ANEB Intrinsic Value
Base Case
Not Available
Base Case Scenario

Fundamental Analysis

How can I assist you today?

Provide an overview
of Anebulo Pharmaceuticals Inc's business.

What risks and challenges
does Anebulo Pharmaceuticals Inc face in the near future?

Summarize the latest earnings report
of Anebulo Pharmaceuticals Inc.

Provide P/E
for Anebulo Pharmaceuticals Inc and its competitors.

Financials

Balance Sheet Decomposition
Anebulo Pharmaceuticals Inc

Current Assets 6.8m
Cash & Short-Term Investments 6.6m
Other Current Assets 171.7k
Non-Current Assets 684.5k
Other Non-Current Assets 684.5k
Current Liabilities 1m
Accounts Payable 318.7k
Accrued Liabilities 694.9k
Efficiency

Earnings Waterfall
Anebulo Pharmaceuticals Inc

Revenue
0 USD
Operating Expenses
-10.7m USD
Operating Income
-10.7m USD
Other Expenses
156k USD
Net Income
-10.5m USD

Free Cash Flow Analysis
Anebulo Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

ANEB Profitability Score
Profitability Due Diligence

Anebulo Pharmaceuticals Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score

Anebulo Pharmaceuticals Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

ANEB Solvency Score
Solvency Due Diligence

Anebulo Pharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Anebulo Pharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ANEB Price Targets Summary
Anebulo Pharmaceuticals Inc

Wall Street analysts forecast ANEB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ANEB is 6.12 USD with a low forecast of 4.04 USD and a high forecast of 8.4 USD.

Lowest
Price Target
4.04 USD
41% Upside
Average
Price Target
6.12 USD
113% Upside
Highest
Price Target
8.4 USD
193% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

ANEB Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

ANEB Price
Anebulo Pharmaceuticals Inc

1M 1M
+6%
6M 6M
-6%
1Y 1Y
+3%
3Y 3Y
-59%
5Y 5Y
-59%
10Y 10Y
-59%
Annual Price Range
2.87
52w Low
1.71
52w High
3.49
Price Metrics
Average Annual Return -36.34%
Standard Deviation of Annual Returns 40.27%
Max Drawdown -81%
Shares Statistics
Market Capitalization 74.4m USD
Shares Outstanding 25 933 200
Percentage of Shares Shorted 0.08%

ANEB Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Anebulo Pharmaceuticals Inc Logo
Anebulo Pharmaceuticals Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

74.4m USD

Dividend Yield

0%

Description

Anebulo Pharmaceuticals, Inc. engages in the provision of pharmaceutical services. The company is headquartered in Lakeway, Texas and currently employs 2 full-time employees. The company went IPO on 2021-05-07. The firm is engaged in developing solutions for people suffering from cannabinoid overdose and substance addiction. The firm's lead product candidate, ANEB-001, is a potent, small molecule cannabinoid receptor antagonist, designed to address the unmet medical need for a specific antidote for cannabinoid overdose. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations. ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within one hour of administration. CB1 antagonists bind to the CB-1 receptor and thereby reverse the action of cannabinoids such as tetrahydrocannabinol (THC). The company has completed Phase I trials.

Contact

TEXAS
Lakeway
1415 Ranch Road 629 South, Suite 201
+15125980931.0
https://www.anebulo.com/

IPO

2021-05-07

Employees

2

Officers

Founder & Chairman
Dr. Joseph F. Lawler M.D., Ph.D.
Chief Scientific Officer
Dr. Kenneth C. Cundy Ph.D.
CEO & Director
Mr. Richard Anthony Cunningham
Principal Accounting Officer, Acting CFO & Secretary
Mr. Daniel V. George
Head of Investor Relations & Public Affairs
Mr. Scott L. Anderson

See Also

Discover More